Methods and compositions for treating cancers and other proliferative disorders
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsOlga Rafikova, Ruslan Rafikov
Life of this patent
Estimating the term…
Loading patent…
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsOlga Rafikova, Ruslan Rafikov
Estimating the term…
Inositol monophosphatase 1 (IMPA1) controls the activity of the primary cell proliferation signaling cascades activated through the inositol-dependent phosphorylation of Akt and PKCs. Furthermore, IMPA1-mediated control of cell proliferation involves the recruitment of cytosolic IMPA1 on a plasma membrane by the receptor for advanced glycation endproducts (RAGE). Interaction between IMPA1 and RAGE redistributes inositols from the cytosolic pool to membrane microdomains and amplifies the synthesis of membrane-bound phosphatidylinositols (PtdIns) to trigger inositol-dependent cell proliferation. Thus, the peptide compositions described herein inhibit the formation of the complex between IMPA1 and RAGE (e.g., a pathogenic complex) to control over-proliferative cells.
An antiproliferative peptide comprising a sequence at least 80% identical to ILWQRRQRRG (SEQ ID NO:
A method of treating a proliferation disease in a subject in need thereof, the method comprising, administering a therapeutically effective amount of an antiproliferative peptide comprising a sequence at least 80% identical to ILWQRRQRRG (SEQ ID NO:
Dependencies are inferred from the claim text.